Also indexed as: Para-Aminobenzoic Acid
Para-aminobenzoic acid (PABA) is a compound that is an
essential nutrient for microorganisms and some animals, but has not been shown
to be essential for people. PABA is considered by some to be a member of the
vitamin B-complex, though its actions differ widely from other B vitamins.
Where is it found?
PABA is found in grains and foods of animal origin.
PABA has been used in connection with the following conditions (refer to the individual health concern for complete information):
Who is likely to be deficient?
Deficiencies of PABA have not been described in humans, and most nutritionists do not consider it an essential nutrient.
How much is usually taken?
Small amounts of PABA are present in some B-complex vitamins and multivitamin formulas. The amount of PABA used in the studies described above ranged from 300 mg to 12 grams per day. Anyone taking more than 400 mg of PABA per day should consult a physician.
Are there any side effects or interactions?
No serious side effects have been reported with 300–400 mg per day. Larger amounts (such as 8 grams per day or more) may cause low blood sugar, rash, fever, and (on rare occasions) liver damage.1 One report exists of vitiligo appearing after ingestion of large amounts of PABA2 and use of amounts over 20 grams per day in small children has resulted in deaths.3 There is also a report of a death from toxic hepatitis in a person with lupus, who took as much as 48 grams per day for six days, followed by 8 grams per day for seven months.4
No interactions between PABA and other nutrients have been reported. However, PABA interferes with sulfa drugs (a class of antibiotics) and therefore should not be taken when these medications are being used.
Are there any drug interactions?
Certain medicines may interact with PABA. Refer to drug interactions for a list of those medicines.
References
1. Kantor GR, Ratz JL. Liver toxicity from potassium para-aminobenzoate. J Am Acad Dermatol 1985;13:671–2.
2. Hughes CG. Oral PABA and vitiligo. J Am Acad Dermatol 1983;9:770 [letter].
3. Worobec S, LaChine A. Dangers of orally administered para-aminobenzoic acid. JAMA 1984;251:2348.
4. Zarafonetis CJD, Grekin RH, Curtis AC, et al. Further studies on the treatment of lupus erythematosus with sodium para-aminobenzoate. J Invest Dermatol 1948;11:359.

Copyright © 2007 Healthnotes, Inc. All rights reserved.
www.healthnotes.com
Learn more about Healthnotes, the company.
Learn more about the authors of Healthnotes.
The information presented in Healthnotes is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or chemist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires September 2008.
2007-09-01